Consun Pharmaceutical Group Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: HKG:1681
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 548 out of 847
Universe
Global Universe 11684 out of 14948
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Mega Lifesciences Public Co. Ltd. |
28.8
Medium
|
350 out of 847 |
Consun Pharmaceutical Group Ltd. |
33.1
High
|
548 out of 847 |
Shandong Sinobioway Biomedicine Co., Ltd. |
36.3
High
|
698 out of 847 |
Zhejiang Tianyu Pharmaceutical Co., Ltd. |
36.3
High
|
700 out of 847 |
Shandong Wit Dyne Health Co., Ltd. |
36.4
High
|
705 out of 847 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Consun Pharmaceutical Group Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Consun Pharmaceutical Group Ltd.'s Management of ESG Material Risk is Weak